Does the Addition of Ginger Decrease Migraine Pain? by Nguyen, Stephanie
Philadelphia College of Osteopathic Medicine 
DigitalCommons@PCOM 
PCOM Physician Assistant Studies Student 
Scholarship Student Dissertations, Theses and Papers 
2020 
Does the Addition of Ginger Decrease Migraine Pain? 
Stephanie Nguyen 
Philadelphia College of Osteopathic Medicine 
Follow this and additional works at: https://digitalcommons.pcom.edu/pa_systematic_reviews 
 Part of the Medicine and Health Sciences Commons 
Recommended Citation 
Nguyen, Stephanie, "Does the Addition of Ginger Decrease Migraine Pain?" (2020). PCOM Physician 
Assistant Studies Student Scholarship. 563. 
https://digitalcommons.pcom.edu/pa_systematic_reviews/563 
This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student 
Dissertations, Theses and Papers at DigitalCommons@PCOM. It has been accepted for inclusion in PCOM 
Physician Assistant Studies Student Scholarship by an authorized administrator of DigitalCommons@PCOM. For 
more information, please contact library@pcom.edu. 
 
 






Stephanie Nguyen, PA-S 
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW 
In Partial Fulfillment of the Requirements For  
The Degree of Master of Science 
In 
Health Sciences – Physician Assistant 
 
 
Department of Physician Assistant Studies 
Philadelphia College of Osteopathic Medicine 
Philadelphia, Pennsylvania 
 









OBJECTIVE: The objective of this selective EBM review is to determine whether or not “does 
the addition of ginger decrease migraine pain”.  
STUDY DESIGN: A systematic review of three peer-reviewed studies published between the 
years of 2011-2018.  
DATA SOURCES: Three double-blinded randomized control trials were chosen from the 
Cochrane Library and PubMed and selected based on patient oriented outcomes and their 
relevance to the clinical questions. The study by Martins et al., (Cephalalgia. 2018; 39(1):68-76. 
doi: 10.1177/0333102418776016) compared the addition of ginger vs placebo. The study by 
Maghbooli et al., (Phytotherapy Research. 2014;28(3):412–415. doi: 10.1002/ptr.4996.) 
compared the addition of ginger vs sumatriptan. The study by Cady et al., (Headache. 2011; 
51:1078–1086) compared the addition of ginger/feverfew extract vs placebo. 
 
OUTCOME(S) MEASURED: The outcome measured was the reduction of migraine pain 2 
hours (2h) post-treatment using patient oriented and reported pain rating using either a four-point 
scale (0= no pain, 1= mild pain, 2= moderate pain, 3=severe pain) or a visual analogue scale 
(VAS).  
 
RESULTS: There was an overall decrease in migraine pain 2h post-treatment with the addition 
of ginger. The study conducted by Martins et al., (Cephalalgia. 2018; 39(1):68-76. doi: 
10.1177/0333102418776016) showed the addition of ginger significantly reduced migraine pain 
compared to placebo after 2h post-treatment reported using a four-point pain scale (p= 0.04). The 
study conducted by Maghbooli et al., (Phytotherapy Research. 2014;28(3):412–415. doi: 
10.1002/ptr.4996.) revealed similar efficacy in reducing migraine pain between the ginger and 
sumatriptan treatment groups with a reduction of 4.6 units (p<0.0001) and 4.7 units (p<0.0001) 
in VAS scores respectively. The study conducted by Cady et al., (Headache. 2011; 51:1078–
1086) had a significant decrease in migraine pain reported using a four-point scale 2h post-
treatment with a decrease from 1.41 to 1.17 (p=0.01). 
 
CONCLUSIONS: The evidence presented in this review reveals that the addition of ginger did 
significantly decrease migraine pain 2h post-treatment. Ginger extract is an affordable 
supplement that is easily accessible. Further research is warranted to evaluate the effects of 
ginger on migraine pain as monotherapy and to determine a therapeutic dose.   
 














 Migraines are a type of primary headache that typically presents as a severe, throbbing, 
unilateral headache lasting 4-72 hours and may be accompanied by nausea and vomiting. 
Although not required for diagnosis migraine sufferers may also experience an aura which may 
present as aphasia, numbness, paresthesia or visual disturbances such as scotomata or 
photophobia.  
 Migraines are a common condition that effects 1 in 7 adults in the US and are the most 
common type of primary headaches that lead emergency department (ED) visits.1,2 In 2010, they 
accounted for over 908,000 visits to the ED with an estimated annual cost over $700 million in 
ED visits.3 Along with the financial cost, there have been several studies that have shown people 
suffering from migraines have reported interference with family and social aspects, finances and 
work leading to a decrease in quality of life.4,5,6 Migraine patients may be encountered by 
physician assistants in many medical specialties including primary care for symptomatic and 
prophylaxis treatment options, neurology to rule out other causes of the neurological symptoms 
associated with a migraine aura and in the ED for abortive treatments. 
 Migraines are thought to arise from neurologic dysfunction where vasoactive compounds 
irritate the trigeminal nerve leading to neurological inflammation. The auras are hypothesized to 
arise from the cerebral cortex, which manifests as the sensory symptoms that many experience 
prior to a migraine onset. They typically are also reoccurring and may have triggers including but 
not limited to missed meals, sleep deprivation, dehydration and stress.  
 Currently, the basis of treatment is avoidance of known triggers, symptomatic and 
prophylactic therapy. During an acute attack resting in a dark and quiet room along with simple 
analgesics such as non-steroidal anti-inflammatories including acetaminophen, ibuprofen and 
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aspirin, may alleviate pain. In more severe instances stronger prescription medication may be 
necessary. Ergotamines or triptans may be used for their vasoconstrictive properties, but should 
be avoided if there is a history of ischemic stroke, peripheral vascular disease, coronary artery 
disease, uncontrolled hypertension and during pregnancy. Ergotamines and triptans should not be 
used adjunctively or within 24 hours of each other due to the combined vasoconstrictive effects. 
Prophylaxis management includes treating comorbidities and choosing medication based on an 
individual basis. These include beta-blockers, antidepressants, antiepileptic drugs, botox and 
acupuncture. In the ED morphine, an opioid analgesic, is used as the main abortive therapy.7 Due 
to the addictiveness of opioids and the recurrent nature of migraines, it is important to consider 
other adjunctive treatment options to quickly address migraine pain in acute settings that can be 
taken regularly.  
 Ginger extract, known for its anti-inflammatory properties, have been used in past studies 
to treat migraines. Its active compounds gingeroles and shogaols inhibit cyclooxygenase-2 
(COX-2) and 5-lipoxygenase (5-LOX) leading to a decrease in prostaglandins and leukotrienes 
respectively.8 Some studies have also reported that ginger has the potential to reduce platelet 
aggregation.9 Given its anti-inflammatory properties, this review evaluates the effect of ginger on 
migraine pain in three double-blinded randomized control trials.  
 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not “does the 
addition of ginger decreases migraine pain?” The hypothesis is that the addition of ginger will 
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METHODS 
 Three double-blinded randomized controlled trials (RCT) were reviewed to assess the 
efficacy of the addition of ginger on migraine pain, as either adjunct therapy or monotherapy. 
This review focused on the general patient population that suffered from migraines. The efficacy 
was compared to a placebo group in two of the three studies and sumatriptan in the third study.10-
12 All studies assessed a patient oriented outcome by measuring pain reduction using a patient 
reported four-point pain scale score or visual analogue score (VAS).10-12 This systematic review 
focuses specifically on the effects of ginger in decreasing migraine pain 2 hours (2h) post-
treatment. 
 A specific search criteria was used to select these studies. Keywords used during the 
search included “ginger” and “migraine”. All three studies were published in peer-review 
journals, printed in English and selected from the Cochrane Library or PubMed. Inclusion 
criteria included any RCT within the last ten years and exclusion criteria included anything 
published before 2008. Statistical analyses in each study used either odds ratio (OR), ANOVA or 
student t-tests with p-values to determine statistical significance defined as p <0.05. 10-12 The 
demographics, inclusion and exclusion criteria of each study is presented below in Table 1. 10-12    
 
OUTCOMES MEASURED 
 The studies used patient oriented and self-reported results. Martins et al., evaluated 
change in pain intensity using a four-point scale (0= no pain, 1= mild pain, 2= moderate pain, 
3=severe pain) at 0.5h, 1h, 1.5h and 2h post-treatment.10 Maghbooli et al., evaluated headache 
severity using a VAS at 0.5h, 1h, 1.5h, 2h, and 24h post-treatment.11 Cady et al., measured 
headache severity on a four-point scale (0= no pain, 1= mild pain, 2= moderate pain, 3=severe 
pain) at 1h  
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and 2h post-treatment.12 This article will only focus on migraine severity 2h post-treatment. 
Table 1. Demographics of included studies for Ginger and Migraine pain 
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RESULTS 
 The study conducted by Martins et al., was a single double blinded, randomized clinical 
study that included 60 participants, 8 males and 52 females, from the ED of Vera Cruz hospital 
in Brazil.10 The participants were randomly allocated into control and treatment groups in a 1:1 
ratio using a randomized sequence software generator. 10 In addition to the 100mg IV of 
ketoprofen received by both groups, the experimental group (n=30) received 400mg of ginger 
extract as adjunct treatment and the control group (n=30) received an odorless, placebo capsulate 
with the same color and format as the experiment.10 There was no noted significant difference 
between the groups before the start of the trial. 10  It is noted that the exclusion criteria included a 
history of anticoagulants use due to the anti-platelet effects of ginger.9,10 The complete list of 
inclusion and exclusion criteria can be found in Table 1. No participants withdrew or were lost to 
follow up during this trial. 10 
 The outcomes in the study evaluated headache severity using self-reported pain ratings on 
a four-point scale (0= no pain, 1= mild pain, 2= moderate pain, 3=severe pain) 2h after 
treatment.10 The study used crude odds ratio (OR) with a 95% confidence interval (CI) to 
compare the treatment response of ginger extract vs placebo.10 P values <0.05 were considered 
statistically significant. It was observed that the reduction in headache pain from severe/mod to 
mild/no pain in participants that received ginger extract at 2h post-treatment as compared to the 
placebo was significant (p=0.04) as shown in Table 2.10 There was a higher proportion of 
patients that reported being pain free 2h post-treatment with ginger extract vs the placebo (56.7 
vs 33.3, p=0.03).10 The OR of 7.25 with a CI of 0.81-64.45 (p=0.07) after 2h can be found in 
Table 3.10  The OR of 7.25 suggests that improvement in headache severity is 7.25 times higher 
in patients that received ginger as part of their treatment as compared to the placebo indicating a 
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strong association. However, the p-value of 0.07 makes this association not statistically 
significant. 
Table 2. Reduction in migraine intensity reported by four-point scale10 
 
Time 2h 
Placebo 0.97 +0.07 
Ginger 0.81 +0.04 
p-value 0.04 
 








 The study conducted by Maghbooli et al., was a single double blinded, randomized 
clinical study with 100 participants, 71 females and 29 males, enrolled from the Neurology 
Clinic of Zanjan Vali-e-Asr Hospital in Iran.11 The participants were randomly assigned to two 
coequal groups.11 Both groups received a box containing five capsules of either 50mg 
sumatriptan for the control group (n=50) or 250mg powder ginger rhizome for the experimental 
group (n=50).11 Participants were kept on their maintenance therapy and were advised to take 
one capsule with the onset of their migraine for one-month.11 There was no noted significant 
difference between the groups before the start of the trial.11 It is noted that the exclusion criteria 
included a history of bleeding diathesis or use of anticoagulants due to the anticoagulant effects 
of ginger and ischemic heart disease or Prinzmetal’s angina due to the vasoconstrictive effects of 
sumatriptan.11 The complete list of inclusion and exclusion criteria can be found in Table 1. No 
participants withdrew or were lost to follow up during this trial.11 
 The outcomes in the study evaluated the headache severity using self-reported visual 
analogue scale (VAS) after 2h of treatment administration.11 Results were analyzed using student 
t-tests and two-tailed p-values to assess treatment response, with p<0.05 considered significant.11  
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Similar efficacy at 2h post-treatment was observed in sumatriptan and ginger groups, revealing a 
unit reduction of 4.7 (p<0.0001) and 4.6 (p<0.0001) on the VAS respectively.11 The continuous 
data presented in the study was converted into dichotomous data by defining “improvement” as 
patients with a baseline “moderate or severe” headaches that measured “free of headaches” after 
2h, and “no improvement” as patients that measured “mild headaches” after 2h. This was done 
for both the ginger and sumatriptan groups and can be found in Table 4. The NNH indicates that 
for every 34 people that are treated with ginger, one person will have a negative or adverse 
effect, making this a small treatment effect.  The relative benefit increase (RBI) of 5.27% further 
supports this intervention to have a small treatment effect. 
Table 4. Efficacy of Ginger in Reducing Migraine Pain  
 
Study EER CER RBI ABI NNT  NNH 
Maghbooli et 
al., 11 
60.7% 63.9% 5.27% -0.032 ---- 34 
Cady et al., 12 57.0% 37.9% 50.4% 0.191 6 ---- 
 EER: experimental event rate; CER: control event rate; RBI: relative benefit increase;  
 ABI: absolute benefit increase; NNT: number needed to treat; NNH: number needed to harm 
 
 The study conducted by Cady et al., was a double blinded, randomized clinical study with 
60 participants, 14 males and 46 females, conducted at three sites in the USA over a one-month 
period. 12 It is noted that one patient withdrew because of pregnancy.12 The participants were 
randomly assigned using an online generator to the experimental group (n=45) and placebo 
group (n=15) at a ratio of 3:1.12 Both groups were encouraged to administer two units of their 
sublingual drops five minutes apart at the onset of mild migraine pain. 12 Another administration 
of two units in the same manner was acceptable if the headache pain persisted for one hour.12 
Additional rescue medication, once approved by the case investigator, was allowed if pain 
persisted for two hours after the first treatment.12 This study was generalized to children >12 
years old, men and non-pregnant women that suffered from migraines.12 It is noted that the 
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exclusion criteria included a history of anticoagulants use due to the anticoagulant effects of 
ginger.12 The full list of inclusion and exclusion criteria can be found in Table 1.   
 The outcomes in the study evaluated headache severity using self-reported ratings on a 
four-point scale (0= no pain, 1= mild pain, 2= moderate pain, 3=severe pain) after 2h of 
treatment administration.12 The data was analyzed using a 2-way analysis of variance (ANOVA) 
and p-values, with values p<0.05 considered statistically significant.12 It is noted that there was 
“modest randomized imbalance and significant difference between the two groups” at the time of 
treatment.12 The initial headache severity for the active and placebo group was 1.41 and 1.67 
respectively (p=0.01).12 At 2h post-treatment there was a significant decrease in headache 
severity in the experiment group (1.41 to 1.17, p=0.01) compared to the placebo (1.67 to 1.71, 
p=0.81). 12 Thirty-two percent of subjects reported being pain free 2h post-treatment when taking 
sublingual feverfew/ginger as opposed to 16% reported being pain free when taking the placebo 
(p=0.02).12 
 The continuous data presented in the study was converted into dichotomous data by 
defining “improvement” as participants who reported having “no pain or mild pain” after 2h, and 
“no improvement” as participants that measured “moderate or severe” after 2h. This was done 
for both the experiment and placebo group and can be found in Table 4. The NNT of 6 indicated 
that for every six people that are treated with feverfew/ginger sublingual drops there will be one 
person that will have beneficial migraine pain reduction, making this a small treatment effect. 
The RBI of 50.4% further suggests this intervention is a small treatment effect.  
Safety and tolerability  
  Overall, the addition of ginger was well tolerated in all three studies. In the study by 
Martins et al., three participant reported dyspepsia after 0.5h post-treatment and only one 
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participant still had symptoms after 2h post-treatment.10 The study by Maghbooli et al., also 
reported dyspepsia. 11 The study by Cady et al., reported mild adverse effects with the 
ginger/feverfew treatment that were similar to the placebo except for oral numbness. These 
adverse effects included but are not limited to nausea, oral numbness, vomiting and stomach 
cramps. 12  
 
DISCUSSION  
 The three double-blinded RCTs found that the addition of ginger does decrease migraine 
pain, however, the treatment effect is not large. In the study by Martins et al., there was a 
significant decrease in migraine pain after 2h post-treatment when comparing the headache 
severity between the two groups and more patients reported being pain-free when receiving 
ginger after 2h.10 Although the study had an OR of 7.25, this was statistically insignificant 
(p=0.07) as discussed above. In the study by Maghbooli et al., there was no significant difference 
in the efficacy of ginger when compared to sumatriptan in decreasing migraine pain.11 The NNH 
was calculated to be 34 making this treatment effect small. However, this finding should be 
taken into consideration in patients with comorbidities that are contraindications to triptans (i.e. 
hypertension or coronary artery disease) making the addition of ginger a possible treatment 
option. In the final article conducted by Cady et al., there was a significant decrease in migraine 
pain with the addition of ginger, however, the NNT of 6 makes this a small treatment effect. It is 
also noted that the ABI of 0.191 indicates that people that add ginger to their treatment regimen 
are only 19% more likely to have a decrease in migraine symptoms which further suggests this is 
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Limitations 
 Other factors to take into consideration includes the quality, accessibility and dosage 
amount needed for adjunctive treatment. Ginger extract can be found in many drug and food 
stores as a supplement, but it is not approved or regulated by the FDA.13 Although most 
insurance drug coverage plans do not cover vitamins and supplements, ginger can be purchased 
out of pocket for $9-$16 for 120 capsules of 550mg.14 Unfortunately, there are not enough 
studies that have been conducted to determine the therapeutic amount needed to alleviate 
migraine pain which makes dosage recommendations difficult. 
 In the article by Martins et al., one of the limitations was that the treatment plan was to 
use the ginger extract or placebo pill adjunctively with ketoprofen, an analgesic which in itself 
contributes to the decrease in migraine pain severity.10 The article by Maghbooli et al., had a 
similar limitation, in which their participants were allowed to continue their previous 
maintenance therapeutic agents.11 In the article by Cady et al., they used a randomization ratio of 
3:1 feverfew/ginger combination to placebo, which makes the study biased towards the 
experiment group.12 It is also noted that although the placebo did not include an active analgesic, 
feverfew itself has been shown to have anti-inflammatory properties which may have contributed 
to the decrease in headache severity reported by participants.15   
 
CONCLUSION 
 The three articles analyzed in this systematic review suggests that the addition of ginger 
does decrease migraine pain, which supports the hypothesis of this systematic review. However, 
the treatment effects are small as discussed above. When determining whether or not to consider 
ginger as adjuvant treatment for migraine pain it is important to consider all costs and benefits of 
treatment and recommendations should be individualized. 
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 A limitation to this systematic review is that the amount of ginger used in treatment 
groups varied between the studies, which could lead to inconsistent treatment effects since there 
is currently no standardized recommended treatment dose. There is a limited number of studies 
that have been carried out to evaluate the effects of ginger on migraine pain, which also warrants 
future studies. More studies are needed using a larger participant population, studies to evaluate 
ginger’s effects as monotherapy and studies comparing ginger to a placebo rather than another 
medication intervention to fully understand its effects.  The anti-inflammatory effects of ginger 
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